#2777 RISK FACTORS ASSOCIATED WITH OUTCOMES IN PATIENTS WITH HENOCH - SCHӧNLEIN PURPURA NEPHRITIS

Abstract Background and Aims Henoch - Schӧnlein purpura (HSP) is an immuno-mediated small-vessel vasculitis that manifests as non—thrombocytopenic purpura, arthritis or arthralgia, abdominal pain and/or kidney involvement. HSP nephritis can presented micro- macroscopic hematuria, proteinuria, nephrotic nephritic syndrome, well acute renal failure. The aim of the study to identify risk factors associated with unfavorable outcomes in patients nephritis. Method This retrospective enrolled 68 Renal extra-renal symptoms were analyzed. A diagnosis was made when hematuria failure a palpable purpuric eruption joint pains (at least two these three clinical signs) predominant mesangial IgA immune deposits, confirmed by biopsy. subdivided into five classes according manifestation at onset disease: 1) hematuria; 2) mild proteinuria (<1 g/L) ± 3) defined moderate increased serum creatinine hypertension; 4) syndrome; 5) mixed nephritic-nephrotic syndrome. Results Of nephritis, diagnosed biopsy, 41 (60,29%) male 27 (39,71%) female. Age between 18 66 years (mean 37,28 9,34). Duration follow-up 2 28 years. 29 had histories infection preceding presentation. At all urinary abnormalities (only 16,18%; – 44,12%; severe 39,70%). Arthralgias present 49 (72,06%), gastrointestinal involvement 32 (47,05%). function impaired 26,47% patients, 51,47% hypertensive. Mesangial hypercellularity lesions found most (97,06%), endocapillary proliferation 20,58%, segmental sclerosis 32,35%, tubular atrophy/interstitial fibrosis 38,23%. Corticosteroids cyclophosphamide prescribed who histological features rapidly progressing disease. During classical organ diseases seen 55,88% 77,94%. final review progression Risk for during (p<0,001), impairment presentation hypertension follow up (p<0,05), crescents, interstitial atrophy (p<0,001). No significant difference outcome observed relapses organs versus those did not. Conclusion Our results indicated lower GFR, syndrome crescentic outcomes.